Key result
Providing individual patient and aggregate practice feedback to physicians increased the proportion of post-ACS patients achieving guideline-recommended LDL-C thresholds from 0% at baseline to 53.4% at 6-12 months.
Why the study?
Despite contemporary guidelines, many post-ACS patients fail to achieve recommended LDL-C thresholds, motivating an investigation into the care gap, opportunities for lipid-lowering therapy escalation, and reasons for non-prescription.
Does physician feedback improve the achievement of guideline-recommended LDL-C thresholds in post-ACS patients?
Observational (n=248)
Yes
Does physician feedback improve the achievement of guideline-recommended LDL-C thresholds in post-ACS patients?
Answers are grounded in this paper and cite their sources.
Providing individual and aggregate practice feedback to physicians improves the intensification of lipid-lowering therapies and the achievement of LDL-C targets in post-ACS patients.
INTRODUCTION: Despite contemporary practice guidelines, a substantial number of post-acute coronary syndrome (ACS) patients fail to achieve guideline-recommended LDL-C thresholds. Our study aimed to investigate this guideline recommendations-to-practice care gap. Specifically, we aimed to identify opportunities where additional lipid-lowering therapies are indicated and explore reasons for the non-prescription of guideline-recommended therapies. METHODS: ACS patients with LDL-C ≥1.81 mmol/L (70 mg/dL) despite maximally tolerated statin ± ezetimibe therapy (including those intolerant of ≥2 statins) were enrolled 1-12 months post-event from 27 Canadian and US sites from September 2018 to October 2020 and followed up for three visits during the 12 months post-event. We determined the proportion of patients who did not achieve Canadian/US guideline-recommended LDL-C thresholds, the number of patients who would have been eligible for additional lipid-lowering therapies, and reasons behind lack of escalation in lipid-lowering therapies when indicated. Individual patient and aggregate practice feedback, including guideline-recommended intensification suggestions, were provided to each physician. RESULTS: Of the 248 patients enrolled in the pilot study (median age 64 [57, 73] years, 31.5% female and STEMI 27.4%), 75.4% were on high-intensity statins on the first visit. A total of 18.5% of those who attended all 3 visits had an LDL-C measured only at the first visit which was above the threshold. After 1 year of follow-up, 51.9% of patients achieved LDL-C thresholds at either visit 2 or 3. In the context of feedback reminding physicians about guideline-directed LDL-C-modifying therapy in their individual participating patients, we observed an increase in the use of ezetimibe and PCSK9 inhibitor therapy at 3-12 months. This was associated with a significant lowering of the mean LDL-C (from 2.93 mmol/L [baseline] to 2.09 mmol/L [3-6 months] to 1.87 mmol/L [6-12 months]) and a significantly greater proportion of patients (from 0% [baseline] to 38.6% [3-6 months] to 53.4% [6-12 months]) achieving guideline-recommended LDL-C thresholds. The most prevalent reasons behind the non-intensification of LDL-C-lowering therapy with ezetimibe and/or PCSK9i were LDL-C levels being close to target, the pre-existing use of other lipid-lowering therapies, patient refusal, and cost. CONCLUSION: Although most patients post-ACS were on high-intensity statin therapy, almost 50% failed to achieve guideline-recommended LDL-C thresholds by 1-year follow-up. Furthermore, additional lipid-lowering therapies in this high-risk group were underprescribed, and this might be linked to several factors including potential gaps in physician knowledge, treatment inertia, patient refusal, and cost.
No takes yet. Share an insight, caveat, or question.
Alanezi et al. (2024) conducted an observational in Post-Acute Coronary Syndrome Dyslipidemia (n=248). Individual patient and aggregate practice feedback on guideline-recommended lipid-lowering therapy vs. Baseline (pre-intervention) was evaluated on Achievement of guideline-recommended LDL-C thresholds at 6-12 months (Visit 3) (p=0.0244). Providing individual patient and aggregate practice feedback to physicians increased the proportion of post-ACS patients achieving guideline-recommended LDL-C thresholds from 0% at baseline to 53.4% at 6-12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: